Thursday 02 May 2024
Internal Reference Number: FOI_7245
Date Request Received: 16/06/2023 00:00:00
Date Request Replied To: 04/07/2023 00:00:00
This response was sent via: By Email
Request Summary: lung cancer
Request Category: Companies
| Question Number 1: How many patients has your Trust treated in the past 3 months for: • Non-small cell lung cancer (NSCLC) - any treatment • Non-small cell lung cancer (NSCLC) - surgical treatment • Non-small cell lung cancer (NSCLC) - radiotherapy • Non-small cell lung cancer (NSCLC) - systemic anti-cancer treatment (SACT) | |
| Answer To Question 1: How many patients has your Trust treated in the past 3 months for: Data provided for March 23 - May 23 inc • Non-small cell lung cancer (NSCLC) - any treatment - 0 • Non-small cell lung cancer (NSCLC) - surgical treatment - 0 • Non-small cell lung cancer (NSCLC) - radiotherapy - <5 • Non-small cell lung cancer (NSCLC) - systemic anti-cancer treatment (SACT) - 37 | |
| Question Number 2: - How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) • Amivantamab • Atezolizumab monotherapy • Atezolizumab with chemotherapy • Dabrafenib + Trametinib • Durvalumab • Gemcitabine • Nitendanib + Docetaxel • Nivolumab • Osimertinib • Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) • Paclitaxel • Pembrolizumab monotherapy • Pembrolizumab with chemotherapy • Pemetrexed with carboplatin/cisplatin • RET Inhibitors (Pralsetinib, Selpercatinib) • Sotorasib • Tepotinib • Vinorelbine monotherapy or combination with Carboplatin/Cisplatin • Other active systemic anti-cancer therapy [please state] • Palliative care only | |
| Answer To Question 2: Data provided for March 23 - May 23 inc • ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) 6 • Amivantamab 0 • Atezolizumab monotherapy 0 • Atezolizumab with chemotherapy 0 • Dabrafenib + Trametinib <5 • Durvalumab 5 • Gemcitabine 0 • Nitendanib + Docetaxel <5 • Nivolumab 0 • Osimertinib 9 • Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) <5 • Paclitaxel 0 • Pembrolizumab monotherapy 6 • Pembrolizumab with chemotherapy <5 • Pemetrexed with carboplatin/cisplatin <5 • RET Inhibitors (Pralsetinib, Selpercatinib) 0 • Sotorasib <5 • Tepotinib 0 • Vinorelbine monotherapy or combination with Carboplatin/Cisplatin <5 • Other active systemic anti-cancer therapy [please state] docetaxel <5 • Palliative care only - Unable to answer | |
| Question Number 3: Of the NSCLC patients treated with Nivolumab in the past 3 months, how many patients received (surgery) or are scheduled to receive surgical treatment after commencement of the treatment with Nivolumab? | |
| Answer To Question 3: Data provided for March 23 - May 23 inc 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
